Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lurbinectedin

FDA-approved product (powder, intravenous), marketed as Zepzelca.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Lurbinectedin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Neoplasm
  • Small cell lung carcinoma

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antineoplastic agents
FDA pharmacologic class
Alkylating Drug FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.3% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli55.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae47.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis66.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lurbinectedin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lurbinectedin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer

    NCT06385548 · start 2024-05

    Registered record
    Registry ID
    NCT06385548
    Conditions
    Endometrial Cancer
    Interventions
    Lurbinectedin; Dostarlimab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2024-05
    Completion
    2026-04
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Cancer
    InterventionLurbinectedin; Dostarlimab
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn

  • Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer

    NCT05572476 · start 2023-10

    Registered record
    Registry ID
    NCT05572476
    Conditions
    Small Cell Lung Cancer; Platinum-Sensitive Lung Small Cell Carcinoma; Extensive-stage Small-cell Lung Cancer
    Interventions
    Association of lurbinectedin and durvalumab; Association of carboplatin and etoposide
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2023-10
    Completion
    2024-05-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Lung Cancer; Platinum-Sensitive Lung Small Cell Carcinoma; Extensive-stage Small-cell Lung Cancer
    InterventionAssociation of lurbinectedin and durvalumab; Association of carboplatin and etoposide
    PhasePhase 2
    Registry statusWithdrawn

  • Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)

    NCT06088290 · start 2023-09-21

    Registered record
    Registry ID
    NCT06088290
    Conditions
    Leiomyosarcoma
    Interventions
    Lurbinectedin; Doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2023-09-21
    Completion
    2029-08-30
    Enrolment
    469

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeiomyosarcoma
    InterventionLurbinectedin; Doxorubicin
    PhasePhase 3
    Registry statusActive not recruiting

  • A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

    NCT05652686 · start 2023-09-05

    Registered record
    Registry ID
    NCT05652686
    Conditions
    Small Cell Lung Cancer (SCLC); Large Cell Neuroendocrine Cancer (LCNEC); Neuroendocrine Prostate Cancer (NEPC); Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC); Neuroendocrine Carcinomas (NEC); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)
    Interventions
    Peluntamig (PT217); Carboplatin + Etoposide; Paclitaxel.; Atezolizumab; Lurbinectedin; Irinotecan (drug); Topotecan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-09-05
    Completion
    2028-08
    Enrolment
    203

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall Cell Lung Cancer (SCLC); Large Cell Neuroendocrine Cancer (LCNEC); Neuroendocrine Prostate Cancer (NEPC); Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) +2 more
    InterventionPeluntamig (PT217); Carboplatin + Etoposide; Paclitaxel.; Atezolizumab +3 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

    NCT05636111 · start 2023-07-12

    Registered record
    Registry ID
    NCT05636111
    Conditions
    Ovarian Cancer
    Interventions
    Paclitaxel; Bevacizumab; Lurbinectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2023-07-12
    Completion
    2026-12-31
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOvarian Cancer
    InterventionPaclitaxel; Bevacizumab; Lurbinectedin
    PhasePhase 1
    Registry statusRecruiting

  • LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma

    NCT05876715 · start 2023-06-07

    Registered record
    Registry ID
    NCT05876715
    Conditions
    Advanced Soft-tissue Sarcoma
    Interventions
    Lurbinectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-06-07
    Completion
    2026-09-30
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Soft-tissue Sarcoma
    InterventionLurbinectedin
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma

    NCT05734066 · start 2023-05-23

    Registered record
    Registry ID
    NCT05734066
    Conditions
    Refractory Ewing Sarcoma; Relapsed Ewing Sarcoma; Ewing Sarcoma
    Interventions
    Lurbinectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2023-05-23
    Completion
    2028-04-20
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRefractory Ewing Sarcoma; Relapsed Ewing Sarcoma; Ewing Sarcoma
    InterventionLurbinectedin
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

    NCT05574504 · start 2023-05-08

    Registered record
    Registry ID
    NCT05574504
    Conditions
    Metastatic Cancer; Urothelial Carcinoma
    Interventions
    avelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2023-05-08
    Completion
    2028-11
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Cancer; Urothelial Carcinoma
    Interventionavelumab (PD-L1 inhibitor immunotherapy) + lurbinectedin
    PhasePhase 2
    Registry statusWithdrawn

  • Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

    NCT05800587 · start 2023-02-22

    Registered record
    Registry ID
    NCT05800587
    Conditions
    Lung Cancer; Small-cell Lung Cancer; Non Small Cell Lung Cancer
    Interventions
    Carboplatin; Pemetrexed; Paclitaxel; Nab paclitaxel; Docetaxel; Gemcitabine; Etoposide; Irinotecan; Topotecan; Lurbinectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2023-02-22
    Completion
    2029-08-01
    Enrolment
    280

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; Small-cell Lung Cancer; Non Small Cell Lung Cancer
    InterventionCarboplatin; Pemetrexed; Paclitaxel; Nab paclitaxel +6 more
    PhasePhase 2
    Registry statusRecruiting

  • Study of Trilaciclib and Lurbinectidin

    NCT05578326 · start 2022-10-12

    Registered record
    Registry ID
    NCT05578326
    Conditions
    Lung Cancer; Small-cell Lung Cancer
    Interventions
    Trilaciclib; Lurbinectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2022-10-12
    Completion
    2028-12-25
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLung Cancer; Small-cell Lung Cancer
    InterventionTrilaciclib; Lurbinectedin
    PhasePhase 2
    Registry statusRecruiting

  • Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations

    NCT05229588 · start 2022-06-14

    Registered record
    Registry ID
    NCT05229588
    Conditions
    Gastrointestinal Malignancies
    Interventions
    Lurbinectedin 4 MG Injection [Zepzelca]
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2022-06-14
    Completion
    2025-08-04
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Malignancies
    InterventionLurbinectedin 4 MG Injection [Zepzelca]
    PhasePhase 2
    Registry statusCompleted

  • Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors

    NCT05126433 · start 2022-03-03

    Registered record
    Registry ID
    NCT05126433
    Conditions
    Advanced Solid Tumor; Metastatic Solid Tumor; Urothelial Cancer; Poorly Differentiated Neuroendocrine Carcinomas; Homologous Recombination Deficient-Positive Malignancies Agnostic
    Interventions
    Lurbinectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2022-03-03
    Completion
    2023-12-20
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Solid Tumor; Metastatic Solid Tumor; Urothelial Cancer; Poorly Differentiated Neuroendocrine Carcinomas +1 more
    InterventionLurbinectedin
    PhasePhase 2
    Registry statusTerminated

  • Lurbinectedin + Doxorubicin In Leiomyosarcoma

    NCT05099666 · start 2022-02-04

    Registered record
    Registry ID
    NCT05099666
    Conditions
    Advanced Soft-tissue Sarcoma; Metastatic Soft-tissue Sarcoma; Advanced Leiomyosarcoma; Leiomyosarcoma Metastatic
    Interventions
    Lurbinectedin; Doxorubicin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Active not recruiting
    Start
    2022-02-04
    Completion
    2028-07
    Enrolment
    62

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Soft-tissue Sarcoma; Metastatic Soft-tissue Sarcoma; Advanced Leiomyosarcoma; Leiomyosarcoma Metastatic
    InterventionLurbinectedin; Doxorubicin
    PhasePhase 1 / Phase 2
    Registry statusActive not recruiting

  • A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer

    NCT05091567 · start 2021-11-18

    Registered record
    Registry ID
    NCT05091567
    Conditions
    Small-Cell Lung Cancer
    Interventions
    Atezolizumab; Lurbinectedin; Carboplatin; Etoposide
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Active not recruiting
    Start
    2021-11-18
    Completion
    2028-02-28
    Enrolment
    660

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSmall-Cell Lung Cancer
    InterventionAtezolizumab; Lurbinectedin; Carboplatin; Etoposide
    PhasePhase 3
    Registry statusActive not recruiting

  • Lurbinectedin With or Without Irinotecan in Treating Patients With Relapsed or High Risk Metastatic Ewing Sarcoma

    NCT05042934 · start 2021-09-15

    Registered record
    Registry ID
    NCT05042934
    Conditions
    Metastatic Ewing Sarcoma; Recurrent Ewing Sarcoma
    Interventions
    Fine-Needle Aspiration; Irinotecan; Irinotecan Hydrochloride; Lurbinectedin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Withdrawn
    Start
    2021-09-15
    Completion
    2022-08-30
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Ewing Sarcoma; Recurrent Ewing Sarcoma
    InterventionFine-Needle Aspiration; Irinotecan; Irinotecan Hydrochloride; Lurbinectedin
    PhasePhase 1 / Phase 2
    Registry statusWithdrawn